For the Inventor, By the Inventor

Enter assignee name

Södertälje, Sweden

Astrazeneca Ab

Calculating rank

USPTO Granted Patents = 1,534

% Expired Patents = 57.4

CIPO Patents = 64

EPO Patents = 396

Trademarks = 108

Forward Citations = 11,907

Loading Chart...

Loading Chart...

2,184 inventors (with patents filed for the assignee):

Roger Victor Bonnert (32 out of 46 patents)

Stephen Connolly (31 out of 31 patents)

Christopher Walpole (29 out of 31 patents)

4. William Brown (27 out of 27 patents)

5. Stephen Thom (26 out of 60 patents)

6. Stefan Berg (26 out of 28 patents)

7. Bernard Barlaam (25 out of 25 patents)

8. Laurent Francois Andre Hennequin (23 out of 38 patents)

9. Ingemar Starke (22 out of 58 patents)

10. Jason Grant Kettle (22 out of 33 patents)

11. Maurice Raymond Verschoyle Finlay (22 out of 28 patents)

12. Andrew Peter Thomas (22 out of 47 patents)

13. Brian Springthorpe (22 out of 26 patents)

14. Kurt G Pike (22 out of 26 patents)

15. Abdelmalik Slassi (21 out of 59 patents)

Core Competencies:

Medical Injector

PCSK9 Inhibitors

Cancer Therapies

Pharmaceutical Composition

Arginase Inhibitors

Dapagliflozin

Immunofluorescence

Chemical Compounds

Inhaler

Protein Kinase B Inhibitors

Chimeric Antigen Receptors

Dendrimer Formulations

1,534 patents: Sort by Forward Citations

1. 12760009 - Certain 3-azabicyclo[3.1.0]hexanes as GLP-1 receptor modulators (2026-10-13),

2. 12758722 - Chimney shuttling mechanism for an inhaler (2026-10-13),

3. 12758555 - Pharmaceutical formulations (2026-10-13),

4. D1150447 - Medical injector (2026-09-29),

5. 12747223 - N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)quinoline-4-carboxamides (2026-09-29),

6. 12741971 - Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as GLP-1 receptor modulators (2026-09-22),

7. 12729196 - N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides (2026-09-08),

8. 12702663 - Automated assessment of wound tissue (2026-08-11),

9. 12698282 - Inhibitors of myeloperoxidase (2026-08-04),

10. 12691113 - Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies (2026-07-28),

11. 12678444 - Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer (2026-07-14),

12. 12668785 - COMBINATION TREATMENT BY ADMINISTERING A RECOMBINANT APYRASE PROTEIN IN CONJUNCTION WITH A P2Y12 INHIBITOR (2026-06-30),

13. 12667541 - Dry powder formulation for pulmonary delivery and methods of use (2026-06-30),

14. 12653828 - POLQ inhibitors (2026-06-16),

15. D1126392 - Inhaler (2026-05-12),

Company Overview

AstraZeneca AB, headquartered in Södertälje, Sweden, is a global biopharmaceutical company specializing in the development and manufacturing of innovative pharmaceutical formulations. The organization focuses on a range of therapeutic areas, including oncology, cardiovascular, renal, and metabolic diseases. Key technological domains encompass medical injectors, PCSK9 inhibitors, cancer therapies, and various pharmaceutical compositions. AstraZeneca is committed to advancing healthcare through cutting-edge research and the development of novel chemical compounds and treatments.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

1,534 Patents

#1 in Södertälje

#4 in Sweden

#647 in the World

Södertälje, Sweden

Astrazeneca Ab

Forward Citations = 11,907

2,184 inventors:

Roger Victor Bonnert (32 out of 46 patents)

Stephen Connolly (31 out of 31 patents)

Christopher Walpole (29 out of 31 patents)

4. William Brown (27 out of 27 patents)

5. Stephen Thom (26 out of 60 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Astrazeneca Ab. Retrieved from https://idiyas.com/company/astrazeneca-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…